Image Not Found On Media Library
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Pre-Order CRaFT 2025
    • 2024 CRaFT Report
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-r
Image Not Found On Media Library
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Pre-Order CRaFT 2025
    • 2024 CRaFT Report
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Files Under Consideration Holds Steady at 30

August 15, 2021
-
Market Access News
-
Posted by MORSE - 4 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): July 2021 Trends and Insights

 

July 2021 Highlights:

  • 5 products completed CADTH review
  • 5 products initiated pCPA negotiations
  • 3 negotiations were completed with an LOI
  • 1 negotiation was closed without an LOI
  • 1 file was closed without negotiation

 

Key Take-Aways:

  • CADTH released no non-oncology recommendations in July. The volume of files under consideration remains relatively stable in July at 30, with no decrease in the average time under consideration.
  • July pCPA activity continues to be high with the most active negotiations (42) over the past year and a continued slight decline in the ratio of under consideration to active files. The pCPA picked up 5 files this month (down from 12 last month). Three oncology files were initiated slightly more quickly than the non-oncology files. Also, three of the five newly initiated files have previous LOIs in place for other indications (Ofev, Lynparza and Bavencio). Ajovy, for migraine, will join Aimovig under negotiation for a similar indication.
  • 2 of the 3 negotiations (Rozlytrek and Suboxone film) were completed relatively quickly in July, faster than average negotiation times. One file was not successfully negotiated and was closed without a LOI (Stelara for ulcerative colitis, which has closed previously as well) and Zeposia for MS will not be negotiated following a negative CADTH and INESSS recommendation.
  • There remain 8 files under consideration for greater than 6 months despite the initiation of a number of files in June and the creation of the Targeted Negotiation Process. The number of protracted negotiations remains low at 2. There is consistency in the number of files adjudicated since March hovering at 5.

 

Files Under pCPA Consideration*:

CADTH issued 5 new recommendations in July (30 files under pCPA consideration as of July 31st – down from 31 in June).

PRODUCT INDICATION SPONSOR Reimbursement Decision Type REC’N* DATE
Imfinzi (Durvalumab) Extensive-stage small cell lung cancer AstraZeneca Canada Inc. Conditional Reimbursement Oncology 2021-07-09
Braftovi and Mektovi (encorafenib and binimetinib) Advanced Melanoma Pfizer Canada ULC. Conditional Reimbursement Oncology 2021-07-08
Braftovi (encorafenib) Metastatic colorectal cancer Pfizer Canada ULC. Conditional Reimbursement Oncology 2021-07-08
Keytruda (pembrolizumab) Colorectal cancer Merck Canada Inc. Conditional Reimbursement Oncology 2021-07-09
Unituxin (Dinutuximab) Neuroblastoma United Therapeutics Conditional Reimbursement Oncology 2021-07-07

*Note: MORSE defines “Rec’n date” as the time of‘final recommendation issued to sponsor and drug plans’, and the ‘Time to Initiate’ as the time between ‘final recommendation issued to sponsor and drug plans’ and ‘pCPA Engagement Letter Issued’.
  

 

Signals Decoded:

 

CADTH released no non-oncology recommendations in July. The volume of files under consideration remains relatively stable in July at 30, with no decrease in the average time under consideration.

 

Negotiation Initiation:

The pCPA initiated 5 new negotiations in July (42 active negotiations as of July 31st) – up from 41 in June.

PRODUCT INDICATION SPONSOR CATEGORY INITIATE DATE TTI*
Ofev (Nintedanib) chronic fibrosing interstitial lung diseases Boehringer Ingelheim (Canada) Ltd. Ltee Non-oncology 2021-07-16 142
Polivy (Polatuzumab Vedotin) relapsed or refractory diffuse large B-cell lymphoma Hoffmann-La Roche Limited Oncology 2021-07-21 76
Lynparza (olaparib) Metastatic Castration-Resistant Prostate Cancer (mCRPC) AstraZeneca Canada Inc. Oncology 2021-07-07 62
Bavencio (Avelumab) Urothelial Carcinoma (UC) EMD Inc. Canada Oncology 2021-07-22 105
Ajovy (fremanezumab) migraine Teva Canada Inc. Non-oncology 2021-07-16 114

*Time to Initiation (TTI) – Time between ‘final recommendation issued to sponsor and drug plans’ and ‘pCPA Engagement Letter Issued’.

 

 

Signals Decoded:
 
July pCPA activity continues to be high with the most active negotiations (42) over the past year and a continued slight decline in the ratio of under consideration to active files. The pCPA picked up 5 files this month (down from 12 last month).
 
Three oncology files were initiated slightly more quickly than the non-oncology files. Also, three of the five newly initiated files have previous LOIs in place for other indications (Ofev, Lynparza and Bavencio). Ajovy, for migraine, will join Aimovig under negotiation for a similar indication.

 

Completed Negotiations:

The pCPA completed 3 negotiations with a Letter of Intent (LOI) in July 2021, the same number as in June.

PRODUCT INDICATION Sponsor Type Status LOI DATE TTN*
Rozlytrek (entrectinib) ROS1-positive Non-Small Cell Lung Cancer Hoffmann-La Roche Limited Oncology Completed 2021-07-06 63
Xtandi (Enzalutamide) Metastatic Castration Sensitive Prostate Cancer (mCSPC) Astellas Pharma Inc. Oncology Completed 2021-07-30 273
Suboxone (film) (Buprenorphine/naloxone) Opioid drug dependence (substitution treatment) Indivior UK Limited Other Completed 2021-07-15 135

* TTN = Time to Negotiate in calendar days
 

Closed Negotiations:

The pCPA closed 1 negotiation without an LOI in July 2021.

PRODUCT INDICATION Sponsor Type Status LOI DATE TTN*
Stelara (Ustekinumab) Ulcerative colitis Janssen Inc. Non-oncology Closed 2021-07-28 92

 

Not Negotiated:

The pCPA declined negotiations on 2 files in June 2021. 

PRODUCT INDICATION Sponsor Type Status Negotiation End DATE TTD*
Zeposia (ozanimod) Multiple Sclerosis, relapsing – remitting Celgene Inc. Non-Oncology Not Negotiated 2021-07-29 36

*TTD = Time to Decline in calendar days

 

Signals Decoded:
 
2 of the 3 negotiations (Rozlytrek and Suboxone film) were completed relatively quickly in July, faster than average negotiation times.
 
One file was not successfully negotiated and was closed without a LOI (Stelara for ulcerative colitis, which has closed previously as well) and Zeposia for MS will not be negotiated following a negative CADTH and INESSS recommendation.

  

  


  

 

Signals Decoded:
 
There remain 8 files under consideration for greater than 6 months despite the initiation of a number of files in June and the creation of the Targeted Negotiation Process. The number of protracted negotiations remains low at 2.
 
There is consistency in the number of files adjudicated since March hovering at 5.

 
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
MORSE Strengthens Public Payer Expertise
NEXT POST →
Highly Productive Month for pCPA Initiations

Contact Us

MORSE Consulting Inc.

Toronto | Ottawa, Canada

+1-647-717-3179 (Toronto)

+1-613-864-8645 (Ottawa)

info@morseconsulting.ca

Pre-Order 2025 Report

2025 Canadian Reimbursement and Forecasting Timelines Report

Social
Connect & Follow:
Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Files Under Consideration Holds Steady at 30
Learn More
Learn More